Franklin Resources Inc. held its stake in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 395,000 shares of the company’s stock at the end of the fourth quarter. Franklin Resources Inc. owned approximately 5.05% of Trillium Therapeutics worth $2,232,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Creative Planning increased its stake in shares of Trillium Therapeutics by 37.3% in the third quarter. Creative Planning now owns 8,100 shares of the company’s stock valued at $120,000 after buying an additional 2,200 shares in the last quarter. Oxford Asset Management increased its stake in shares of Trillium Therapeutics by 47.7% in the fourth quarter. Oxford Asset Management now owns 24,660 shares of the company’s stock valued at $139,000 after buying an additional 7,967 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Trillium Therapeutics by 1,080.0% in the third quarter. Wells Fargo & Company MN now owns 11,800 shares of the company’s stock valued at $175,000 after buying an additional 10,800 shares in the last quarter. Susquehanna International Group LLP acquired a new stake in shares of Trillium Therapeutics during the third quarter valued at $372,000. Finally, Polar Capital LLP acquired a new stake in shares of Trillium Therapeutics during the third quarter valued at $488,000. 42.78% of the stock is currently owned by institutional investors.
Shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) opened at 6.90 on Tuesday. Trillium Therapeutics Inc. has a one year low of $4.50 and a one year high of $17.70. The firm has a 50-day moving average price of $5.93 and a 200 day moving average price of $9.05. The firm’s market cap is $54.13 million.
Your IP Address:
Several equities research analysts have weighed in on the company. Zacks Investment Research downgraded Trillium Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 9th. Cowen and Company reissued a “buy” rating on shares of Trillium Therapeutics in a report on Monday, December 5th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Trillium Therapeutics currently has an average rating of “Buy” and an average target price of $21.15.
Want to see what other hedge funds are holding TRIL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR).
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024787/trillium-therapeutics-inc-tril-position-held-by-franklin-resources-inc.html
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.